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Abstract
Ever since the introduction of highly active antiretroviral 
therapy (ART) in 1995, HIV infection has been linked to “met-
abolic” complications (insulin resistance, dyslipidemia, os-
teoporosis, and others). Studies suggested increased rates 
of myocardial infarction, renal insufficiency, neurocognitive 
dysfunction, and fractures in HIV-postitive patients. Even 
long-term suppression of HIV seemed to be accompanied 
by an excess of deleterious inflammation that could pro-
mote these complications. The aims of this viewpoint paper 
are to summarize recent data and to examine the possibility 
that the problem of aging-related morbidity in HIV might 
not be as dramatic as previously believed.
© 2018 S. Karger AG, Basel
Introduction
The dramatic reduction in AIDS-related mortality 
seen after the introduction of highly active antiretroviral 
therapy (ART) in 1995 was soon followed by reports sug-
gesting metabolic problems in HIV-positive patients 
treated with the promising new ART agents. These in-
cluded insulin resistance, dyslipidemia, osteoporosis, and 
others. Subsequent studies suggested increased rates of 
myocardial infarction (MI), renal insufficiency, neuro-
cognitive dysfunction, and bone fractures in HIV-posi-
tive patients compared to HIV-negative control persons 
(Fig. 1).
Each of these conditions has long been known to occur 
more frequently as individuals get older, hence the more 
recent notion of “aging-related” complications and the 
fear that prolonged survival in HIV-positive persons 
might come at the price of accelerated aging. Potential 
risk factors included toxicity of ART and other medica-
tions, prior immunosuppression, more smokers, and 
more drug users among HIV-positive persons. Disturb-
ingly, even long-term successful suppression of HIV 
seemed to be accompanied by an excess of deleterious Tanja Engel and Marieke Raffenberg contributed equally to this work.
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Fig. 1. Major metabolic complications of HIV infection.
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inflammation that could promote atherosclerosis, osteo-
porosis, or neurocognitive decline. The question then 
was, is HIV invariably followed by premature aging even 
under the best of circumstances (healthy lifestyle, optimal 
ART adherence, no smoking or drug use)?
In this viewpoint paper, our aims are to summarize 
recent data and to examine the possibility that the prob-
lem of aging-related morbidity in HIV might not be as 
dramatic as previously believed.
HIV Infection: More Cardiovascular Events in Initial 
Reports, Less Dramatic Findings in More Recent 
Studies
One of the strongest risk factors for cardiovascular 
(CV) events is advancing age. More than 10 years ago, 
large studies (> 3,000 HIV-positive and > 1 million HIV-
negative persons) suggested that HIV-positive persons 
have 2- to almost 4-fold increased CV event rates and 
more fractures compared to HIV-negative persons, espe-
cially when > 55 years old [1, 2]. However, no informa-
tion on smoking or on the prescribed ART agents was 
available in these studies that came from a single health-
care system in Boston, MA, USA, that were database-
derived, and where stringent event validation was not 
possible. Since then, accelerated atherosclerosis in HIV-
positive persons has become a widely held notion, which 
might be related to procoagulant and proinflammatory 
mechanisms in the setting of immunosuppression, ad-
verse viral effects on endothelial and other cells, deleteri-
ous metabolic effects of certain ART agents, and a high 
prevalence of smoking and substance use among HIV-
positive persons.
Interestingly, a recently updated analysis from the 
same group in Boston, MA, USA, showed a much small-
er difference between HIV-positive and HIV-negative 
persons with regard to CV events [3]. A widely cited 
study then estimated an approximately 50% increased 
CV event rate among HIV-positive compared to HIV-
negative US veterans, after adjusting for Framingham 
risk factors, comorbidities, and substance use [4]. It is 
uncertain whether these findings can be generalized to 
non-veterans. A recent large analysis (29,169 HIV-posi-
tive persons in the USA and Canada, 335 MIs) applied 
stringent MI validation, excluded type 2 MIs, and com-
pared event rates with a well-established HIV-negative 
cohort study. HIV infection was barely significantly as-
sociated with a 21% increased CV incidence rate (95% 
confidence interval, 2–45%), and no significant differ-
ence in event rates was seen in those aged > 60 years ir-
respective of HIV infection [5].
Of note, the incidence rate of CV events was the same 
in 2 recent European cohort studies, when comparing 
HIV-positive and HIV-negative never-smokers in Den-
mark [6], and irrespective of smoking status in a HIV co-
hort study in Switzerland [7]. While these findings re-
quire further confirmation, a relevant emerging conclu-
sion is that studies over the past few years suggest smaller 
differences in CV event rates between HIV-positive and 
HIV-negative persons than previously recorded, and 
smoking appears to be a more important CV risk factor 
than HIV status.
Might Cardiac Imaging Be Useful to Detect Early 
Subclinical Atherosclerosis?
Given the prevalent notion of an increased CV event 
rate in HIV-positive persons, considerable interest has 
been generated by the prospect of early detection of (“sub-
clinical”) atherosclerosis before hard CV events have oc-
curred. However, initial studies using carotid intimal me-
dial thickness and coronary artery calcium (CAC) deter-
mination have not consistently shown an increased 
atherosclerosis prevalence in HIV-positive compared to 
HIV-negative persons [8]. This might be because coro-
nary artery plaque in part is noncalcified in patients aged 
< 50 years, and HIV-positive persons may experience CV 
events at a young age – perhaps earlier than HIV-negative 
persons, at least in some studies [9].
Coronary CT angiography (CCTA) can accurately de-
tect noncalcified plaque and predicts CV events better 
than CAC or carotid intimal medial thickness [10]. In re-
cent large CCTA studies from the USA, inconsistent re-
sults were recorded, i.e., an increased [11] and a similar 
[12] prevalence of noncalcified plaque in HIV-positive 
compared to HIV-negative persons. An increased dura-
tion of ART was associated with subclinical atherosclero-
sis in these studies [11, 12], but individual ART agents 
were not associated [13], suggesting that achieving and 
maintaining virological control may be the more impor-
tant factors. The lower coronary artery disease rates in 
central/southern Europe compared to North America 
highlight the need for European studies. We have recent-
ly completed a CCTA/CAC study in Switzerland (428 
HIV-positive and 276 HIV-negative participants) [14]. 
The HIV-positive patients had a similar prevalence of 
high-risk plaque, but less calcified plaque and lower coro-
nary segment severity and involvement scores. As in the 
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above-mentioned European studies on CV endpoints [6, 
7], traditional CV risk factors contributed to subclinical 
atherosclerosis but HIV infection did not.
Have Studies on Telomere Length Improved Our 
Understanding of Aging in HIV?
We think that this is not yet the case. While biomarkers 
of inflammation and T-cell activation are associated with 
CV endpoints in HIV, our understanding of the precise 
mechanisms leading to possibly premature aging in HIV-
positive persons remains limited. Leucocyte telomere 
length (TL) is considered to be a marker of CV aging and 
increased biological age, and studies on TL are, therefore, 
of particular interest in the field of HIV. Notably, most data 
on TL in HIV-positive persons is limited by a cross-sec-
tional design and the absence of appropriate controls; how-
ever, it tends to suggest shorter TL in HIV-positive persons 
compared to HIV-negative controls [15, 16]. Preliminary 
data on patients with pre- and post-HIV seroconversion 
measurements suggests that significant TL shortening oc-
curs in the setting of HIV seroconversion [17]. However, 
there is no solid data suggesting that, after seroconversion, 
HIV-positive persons have accelerated TL shortening over 
time compared to HIV-negative persons. Factors such as a 
longer duration of HIV infection and HIV maximal viral 
load [15] may be associated with shorter TL and, therefore, 
– possibly – with aging and atherosclerosis. Large studies 
in the general population have recorded an association be-
tween shorter TL and more atherosclerosis [18], but no 
such data is yet available in the setting of HIV.
Essentially Normal Life Expectancy with ART in 
Recent Years 
While aging might be accelerated, it is important to 
note that the mortality of HIV-positive persons has not 
been increasing in recent years. For example, the annual 
mortality curve of HIV-positive persons in Switzerland 
after 1995 is a flat line, with no evidence for any recent 
increase in the death rate from metabolic complications 
[19]. In addition, when injecting drug users (who have 
higher death rates compared to non-users) are excluded 
from mortality analyses, a consistent finding from nu-
merous cohorts is that persons with well-controlled HIV 
infection have survival rates that approach those of HIV-
negative persons [20]. Indeed, over the past 10 years, the 
mortality “gap” between HIV-positive and HIV-negative 
persons in Western countries has considerably narrowed 
in the setting of effective ART [21].
There are nearly twice as many smokers among HIV-
positive men and women in the USA as in the general 
population, and attempts to quit are made far less fre-
quently and less successfully in the former group [22]. 
Encouragingly, smoking rates have been decreasing in 
the past 10 years in HIV-positive persons in Switzerland, 
even in the subgroup which is most likely to smoke, i.e., 
injecting drug users [23].
Bone Fractures in HIV – More than Traditional Risk 
Factors and Choice of ART?
Similar to CV events, a large database-derived study 
from Boston, MA, USA, identified a 62% increased frac-
ture prevalence in HIV-positive compared to HIV-nega-
tive persons without any knowledge of factors with a well-
recorded osteoporosis association such as smoking, low 
BMI, specific ART drugs, or corticosteroid use. A widely 
cited meta-analysis then estimated that there was a 7-fold 
increased risk of osteoporosis for HIV-positive persons 
compared to HIV-negative persons [24] and a consider-
ably increased risk of fractures [2].
In more recent studies, a more moderate increase in 
fracture incidence has been reported after adjusting for 
demographics, comorbidities, smoking, alcohol, and 
BMI. For example, in the Women’s Interagency Health 
Study (WIHS), the fracture risk was 32% increased for 
HIV-positive versus HIV-negative women [25], and in 
US veterans, the fracture risk was not increased at all [26]. 
Similar to CV events, the incidence of trauma fracture ap-
pears to be lower in more recent studies and in European 
populations. For example, the incidence of osteoporotic 
fracture per 1,000 person-years was reported to be 5.6 in 
the WIHS, 2.6 in the HIV-positive US veterans, but was 
only 1.35 in the Swiss HIV cohort (including only vali-
dated fractures) [27], and 1.5 in EUROSIDA [28].
Current knowledge suggests that cumulative exposure 
to tenofovir DF (TDF) and to lopinavir/ritonavir increas-
es the fracture risk [29]. In a large-scale analysis, TDF ex-
posure was associated with an increased risk of osteopo-
rotic fracture of 12% per year, this figure increased to 16% 
per year when in combination with lopinavir. The recent 
large EUROSIDA analysis (11,820 persons, 86,118 per-
son-years of follow-up) suggests that not only cumulative 
TDF exposure may be relevant: patients ever exposed to 
TDF had an almost 2-fold increased fracture risk com-
pared to persons never treated with TDF – and with cu-
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mulative TDF exposure, fracture risk did not continue to 
increase [28]. In contrast, integrase inhibitors, such as 
raltegravir, are associated with less osteopenia than either 
TDF [30] or the protease inhibitors atazanavir or daruna-
vir [31]. TAF (tenofovir alafenamide) is a novel version 
of tenofovir with a more favorable kidney- and bone-tox-
icity profile. Bone mineral density (BMD) improves when 
switching to TAF, but – importantly – only when the 
switch is away from TDF [32].
Renal Insufficiency: Increasingly More Common 
in the Aging HIV-Positive Population, But Less 
Nephrotoxic ART Is Now Available
Kidney disease is relatively common in HIV-positive 
persons [33] and includes conditions associated with un-
treated HIV infection (e.g., HIV-associated nephropa-
thy), opportunistic infections, systemic immune response 
to HIV, and ART toxicity [34]. With regard to the effects 
of antiretroviral agents on the kidney, atazanavir may 
promote crystalluria and occasionally causes kidney 
stones, and TDF can cause renal phosphate loss, Fanco-
ni’s syndrome, acute tubular necrosis, and ultimately 
chronic kidney insufficiency. On the other hand, cobici-
stat, dolutegravir, and trimethoprim may increase the se-
rum creatinine concentration and decrease the estimated 
glomerular filtration rate (eGFR) without, however, af-
fecting the actual GFR. Measuring the cystatin clearance 
may help to overcome this problem. The most accurate 
method to estimate GFR in HIV may be the Chronic Kid-
ney Disease Epidemiology Collaboration equations [35].
In recent years, the prevalence and incidence rates of 
kidney disease attributable to aging and metabolic prob-
lems (e.g., diabetes, hypertension, atherosclerosis) have in-
creased [36] and may be higher among HIV-positive com-
pared to HIV-negative persons [7, 37]. Therefore, in aging 
HIV-positive persons, potentially nephrotoxic drugs 
should be avoided. In particular, less nephrotoxic ART is 
now available: a change away from TDF to TAF has ben-
eficial effects on GFR, albuminuria, and proteinuria [32].
Body Composition: Old and New Concerns 
Lipoatrophy is characterized mainly by decreased limb 
and facial fat and may be accompanied by increased trunk 
fat. Lipoatrophy is now recognized as a toxic side effect of 
past use of thymidine analogue HIV drugs [38]. Unfortu-
nately, lipoatrophy is often not reversible, even after a 
switch away from thymidine analogues [40]. Importantly, 
modern ART agents do not appear to cause lipoatrophy 
[39].
Today, concerns about the body composition in HIV-
positive persons have shifted away from lipoatrophy to the 
problem and complications of obesity and abdominal fat 
accumulation. Patients commonly perceive their weight 
gain and obesity as a side effect of ART because the initia-
tion of ART may, in the first 1–2 years, be followed by a 
significant weight gain. This weight gain correlates by far 
most closely with a CD4 nadir < 100, suggesting that this 
most likely represents a re-gain of weight which has been 
previously lost in the setting of progressive immunosup-
pression [41]. In the 2nd and 3rd year after initiation of 
ART, the patients’ weight appears to stabilize, and there is 
no evidence in longitudinal studies that HIV-positive per-
sons continue to gain more weight over time than HIV-
negative controls [42]. In the past 20 years, however, the 
median BMI of HIV-positive persons in Switzerland in-
creased significantly (from 22 to 24), in the setting of ad-
vancing age, better overall health, earlier start of ART, 
fewer AIDS events, and a lower percentage of injecting 
drug users in the HIV-positive population. There is no 
clear evidence that different ART combinations are asso-
ciated with more or less weight gain after adjustment for 
CD4 nadir. It remains to be determined if modern ART 
regimens are associated with abdominal obesity (“apple 
shape”), which, even with a normal BMI, has been linked 
to an increased total and CV mortality rate compared to a 
fat distribution below the waist (“pear shape”) [43].
HIV-Associated Neurocognitive Dysfunction: Poorly 
Understood but Asymptomatic in Most Cases
Even with successful HIV therapy, early studies showed 
that 40–70% of all HIV-positive persons are affected by 
neurocognitive dysfunction. We now know, however, 
that the vast majority of these patients are asymptomatic; 
they are referred to as having asymptomatic neurocogni-
tive impairment (ANI) [44, 45]. The ANI concept and the 
clinical significance of ANI remain debated as, by defini-
tion, the asymptomatic impairment of these patients (in 
at least 2 ability domains) is only uncovered by detailed 
neurocognitive testing and does not interfere with every-
day functioning [46]. Symptomatic cognitive impairment 
has been reported to affect < 5% of all HIV-positive per-
sons in recent years, and when present, it is categorized 
as either mild (mild neurocognitive disorder) or as 
marked (HIV-associated dementia). 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
E-
M
ed
ie
n 
   
   
   
   
   
   
   
   
 
13
0.
60
.4
7.
10
8 
- 6
/2
6/
20
18
 1
:5
0:
53
 P
M
Engel/Raffenberg/Marzolini/Cavassini/
Kovari/Hasse/Tarr
Gerontology6
DOI: 10.1159/000489172
Neurocognitive dysfunction in HIV is currently nei-
ther believed to be relentlessly progressive nor is it be-
lieved to increase the risk for common neurodegenerative 
conditions such as Alzheimer disease – however, so far 
too few HIV-positive persons have reached the age range 
when Alzheimer risk increases in order to study this ques-
tion on a large scale. Clearly, HIV-associated dementia 
has become rare with the introduction of highly active 
ART. 
The initiation of effective modern ART is typically as-
sociated with neurocognitive improvement; however, 
some patients have stable neurocognitive dysfunction 
and some patients even deteriorate. Additional longitudi-
nal studies are required to better understand the outcome 
of HIV-associated neurocognitive dysfunction (HAND) 
in well-controlled patients.
Older age, lower levels of education, immunosuppres-
sion, poor ART adherence, ongoing viral replication, and 
CV risk factors may be associated with HAND [47]. In-
deed, additional factors unrelated to HIV that may cause 
cognitive disorders are quite common in HIV-positive 
persons (identified in approximately 25% of all HIV-pos-
itive patients in a recent Swiss study) [48] and need to be 
excluded prior to concluding that the patient suffers from 
HAND. These include psychiatric disorders such as de-
pression, prior central nervous system (CNS) opportu-
nistic infections, CNS trauma, and illicit drug use.
International HIV guidelines recommend screening 
for HAND, and some groups practice screening at regular 
intervals. When neurocognitive impairment is identified, 
neurological referral for brain imaging and cerebrospinal 
fluid examination is recommended. 
The pathogenesis of HAND remains incompletely un-
derstood and may include ongoing viral replication in the 
CNS, despite HIV control in the peripheral blood, due to 
suboptimal penetration of certain ART agents [49]. Alter-
natively, ART agents may penetrate well into the CNS, 
and ART or certain ART metabolites might cause direct 
neurotoxicity. It remains debated whether CNS “penetra-
tion scores” of individual ART agents are useful for rou-
tine clinical HIV care.
HIV: More Comorbidities and More Frailty, but 
Frailty Assessment Is Controversial in Relatively 
Young HIV-Positive Populations
Numerous factors may contribute to possibly prema-
ture aging in HIV, including ART toxicity, coinfections 
with hepatitis B and C, higher rates of smoking, alcohol, 
and drug use, and residual inflammation despite suppres-
sive ART. Aging-associated conditions are, however, eas-
ier to study than the aging process per se. One important 
notion that has emerged is that comorbidities might not 
occur prematurely in HIV-positive persons but perhaps 
at an increased rate; hence, “accentuated” might be the 
more appropriate term than “accelerated” aging in HIV-
positive persons [50]. Along these lines, HIV-positive 
persons also seem to take more comedications than the 
general population [36, 51].
An important concept in geriatric medicine that has 
only in recent years been applied in the field of HIV is 
frailty. This is variably defined as a syndrome of decreased 
physiological reserve and resistance to stressors and is 
said to be associated with increased morbidity and mor-
tality in the general elderly population [52]. The frailty 
phenotype was defined by unintentional weight loss, self-
reported exhaustion, weakness (grip strength), slow walk-
ing speed, and low physical activity. A number of studies 
now show that HIV infection might be independently as-
sociated with frailty in middle-aged HIV-positive pa-
tients compared with HIV-negative controls [52, 53]. 
Drug use, lower educational level, abnormal fat distribu-
tion, smoking, physical inactivity, increased levels of in-
flammatory biomarkers, and hepatitis C coinfection may 
contribute to frailty [52]. However, there are inconsisten-
cies between studies (e.g., with regard to risk factors and 
any association with certain antiretroviral agents) that 
have limited the generalizability of these results.
Gait speed and grip strength have been recorded to 
predict functional decline and death in elderly popula-
tions. In the multicenter AIDS cohort study [54], average 
grip strength was normal, and there was no difference 
between HIV-positive and HIV-negative men aged > 50 
years. However, HIV-positive men had a more rapid de-
cline in grip strength and clinical weakness occurred ear-
lier. Factors contributing to frailty in HIV may include 
older age, lower BMI, diabetes mellitus, chronic kidney 
disease, peripheral neuropathy, and higher cumulative 
HIV viral load correlated with a greater longitudinal de-
cline in grip strength [54].
Frailty is increasingly recognized as an important 
HIV-associated non-AIDS condition, but frailty assess-
ment is usually not done in routine HIV care – in Swiss 
HIV outpatient clinics, there is limited time, space, and 
personnel for this. Moreover, concern has been expressed 
that the frailty concept was developed in geriatric popula-
tions, i.e., it is unclear if this concept is clinically useful in 
HIV-positive populations whose median age in Western 
countries remains < 50 years. 
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Table 1. Selected drug-drug interactions in aging HIV-positive persons
Drug classes Antiretrovirals Comments
Antacids
H2-receptor blockers
Proton pump inhibitors
Atazanavir
Rilpivirine
•••
Atazanavir/rilpivirine solubility decreases as pH increases
Antacids, H2-receptor blockers: separate drug intake
Proton pump inhibitors: not recommended
Antacids
Divalent cations (iron, 
calcium, magnesium) 
Dolutegravir
Elvitegravir/c
Raltegravir
•
•••
Integrase inhibitors form a complex with divalent cations at the level of the 
gastrointestinal tract which reduces their absorption
Dolutegravir: administer 2 h before or 6 h after antacids or mineral supplements
Elvitegravir/c: separate from antacids or mineral supplements by at least 4 h
Raltegravir: not recommended with aluminum or magnesium antacids. 
Coadministration with calcium carbonate antacids is possible when raltegravir is 
administered twice daily (400 mg b.i.d.) but is not recommended for once daily 
administration of raltegravir (1,200 mg q.d.). Separate administration by at least 4 h with 
mineral supplements
Corticosteroids* Boosted PI
Elvitegravir/c
•
•
Inhibition of steroid metabolism can increase the risk of Cushing syndrome and adrenal 
suppression. Risk is not limited to oral administration but has been documented with 
topical, ocular, intra-articular, intrathecal administration of steroids
Budenoside, fluticasone, triamcinolone, mometasone are contraindicated 
Antidepressants* Boosted PI
Elvitegravir/c
• In general, tricyclic antidepressants should be avoided in older patients due to peripheral 
(constipation, orthostatic hypotension) and central anticholinergic side effects (sedation, 
confusion, delirium). Side effects can be exacerbated by inhibition of their metabolism
Benzodiazepines* Boosted PI
Elvitegravir/c
•
•
Benzodiazepines should be generally avoided in the elderly owing to the increased 
sensitivity to benzodiazepines and increased risk of cognitive impairment, delirium, falls 
and fractures. These effects can be exacerbated by inhibition of their metabolism. Use at 
the lowest dose and for a short duration
Midazolam, triazolam: contraindicated
Vitamin K 
antagonists* Boosted PIElvitegravir/c •• Vitamin K antagonists are metabolized by cytochromes. DDIs with boosted regimens are managed by adjusting the dose according to INRDose adjustments might be needed when switching pharmacokinetic booster, since 
ritonavir has inducing properties on cytochromes whereas cobicistat does not
Direct acting 
anticoagulants* Boosted PIElvitegravir/c •• Substrates of cytochromes and/or transporters and therefore are subject to significant DDIsTheir effect cannot be measured routinely and there are limited data on the management 
of DDIs; therefore, the use of direct acting anticoagulants should be avoided with 
boosted regimens
Antiplatelet agents Boosted PI
Elvitegravir/c
Efavirenz
Etravirine
Nevirapine
•
•
•
Clopidogrel: converted to active metabolite via cytochromes. Boosted regimens and 
etravirine are likely to reduce activation thereby leading to non-responsiveness to 
clopidogrel. Alternatives to clopidogrel should be considered. Note: efavirenz and 
nevirapine may increase activation and therefore should be used with caution
Prasugrel: converted to active metabolite via cytochromes. Coadministration of strong 
inhibitors or inducers of cytochromes was shown to have a limited effect on prasugrel 
antiplatelet effect. Coadministration is possible with boosted regimens, efavirenz, 
etravirine and nevirapine
Ticagrelor: contraindicated with boosted regimens as may substantially increase 
ticagrelor concentrations and the risk of bleeding
Calcium channel 
inhibitors* Boosted PIElvitegravir/c •••
Inhibition of metabolism is expected to increase calcium channel inhibitors 
concentrations and thereby the hypotensive effect
Start at a lower dose and titrate based on response to therapy
Amlodipine: a dose reduction of 50% may be considered
Statins* Boosted PI
Elvitegravir/c
•
•••
Can significantly increase the exposure of some statins and thereby increase the risk of 
rhabdomyolysis
Simvastatin, lovastatin: contraindicated
Other statins: start with low dose and titrate to effect 
Pitavastatin: use of standard dose is possible
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Aging: Higher Risk for Drug-Drug Interactions, More 
Therapeutic Challenges
With aging of the HIV-positive population, medica-
tion-related problems are emerging as an important chal-
lenge, including polypharmacy and a higher risk for drug-
drug interactions (DDIs) [55]. Several antiretroviral 
drugs can interact with comedications used for the treat-
ment of comorbidities in the aging population due to 
their inhibitory properties and/or they induce effects on 
drug-metabolizing enzymes and/or drug transporters 
which can lead to drug toxicity or loss of efficacy of the 
coadministered drug. On the other hand, comedications 
frequently used in elderly individuals (e.g., gastric acid-
reducing agents or mineral supplements) can interfere 
with the absorption of certain antiretroviral drugs and 
thereby compromise their efficacy. Selected DDIs in the 
aging HIV-positive population are shown in Table 1. 
More information can be found in the University of Liv-
erpool’s HIV DDI database (www.hiv-druginteractions.
org). 
Aging of the HIV population is also complicated by 
traditional medication-related problems observed in ge-
riatric medicine. For example, the prescription of corti-
costeroids can complicate blood glucose control in pa-
tients with diabetes. Additional issues regard drug-dis-
ease interactions in the presence of multiple comorbidities 
[56], the decline in the function of organs (which may 
impact pharmacokinetics and thus drug dosing), and ag-
ing can impact drug pharmacodynamics [56] (e.g., elder-
ly individuals can be more sensitive to the effect of drugs 
such as benzodiazepines) [57]. 
Altogether, the presence of comorbidities and age-re-
lated physiological changes predispose elderly HIV-in-
fected individuals not only to a higher risk for DDI, but 
also to the use of inappropriate drugs [58]. Thus, all pre-
scriptions should be carefully reviewed. Finally, it may be 
worth exploring our patients’ perceptions of their ART 
and their comedications in detail: in a recent Swiss study, 
patients attributed more priority to their ART than to 
their comedications, and self-reported adherence to co-
medications was worse [59].
Table 1 (continued)
Drug classes Antiretrovirals Comments
Antidiabetics* Boosted PI
Elvitegravir/c
Dolutegravir
•
•
••
Sulfonylureas: potential increase in concentrations by boosted regimens, monitor effect 
and reduce sulfonylureas dose if needed
Metformin: dolutegravir increases metformin exposure due to inhibition of the renal 
transporter OCT2. Dose adjustment of metformin should be considered when starting 
dolutegravir
Saxagliptin: dose should be limited to 2.5 mg daily with boosted regimens
Exenatide, linagliptin, liraglutide, sitagliptin, vildagliptin: no DDIs with boosted 
regimens
Erectile dysfunction 
agents*
Boosted PI
Elvitegravir/c
•••
Sildenafil: do not exceed 25 mg in 48 h 
Tadalafil: do not exceed 10 mg in 72 h
Vardenafil: do not exceed 2.5 mg in 72 h
Cancer drugs* Boosted PI
Elvitegravir/c
• Multiple cancer drugs are metabolized by cytochromes and therefore are subject to 
significant DDIs leading to cancer drug-related toxicities. Limited data to guide DDI 
management. Antiretroviral drugs with a low potential for metabolic DDIs (raltegravir, 
dolutegravir) should be favored when possible
Non-steroidal anti-
inflammatory drugs
TDF • Coadministration may increase the risk of nephrotoxicity. Avoid long-term use and 
closely monitor renal function
For more detailed information, visit www.hiv-druginteractions.org, or refer to [64, 65]. 
“Boosted” refers to boosting with either ritonavir or cobicistat. 
c, cobicistat; DDI, drug-drug interactions; INR, international normalized ratio; PI, protease inhibitors; TDF, tenofovir disoproxil 
fumarate. * Non-nucleoside reverse transcriptase inhibitors such as efavirenz, etravirine, and nevirapine are predicted to lower the concentra-
tions of some comedications. Dose adjustment of the comedication might be needed.
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What Should We Do about Metabolic Complications 
in HIV?
Most importantly, the same health recommenda-
tions as for the general population also apply to patients 
living with HIV: healthy nutrition, physical activity, 
smoking cessation, as well as treatment of hypertension 
and dyslipidemia. International guidelines now recom-
mend screening for the most important comorbidities. 
To prevent the loss of BMD and to lower the risk of frac-
tures during ART, it is reasonable to start concomitant 
vitamin D3 (and calcium supplements, if dietary calci-
um intake is inadequate), because BMD loss tends to be 
most pronounced in the first year following ART initia-
tion, in particular with TDF, and tends to plateau after 
that [60].
Some HIV experts would recommend avoiding pro-
tease inhibitors altogether, given that they compare un-
favorably with non-nucleoside reverse transcriptase in-
hibitors or integrase inhibitors with regard to multiple 
metabolic endpoints. Similarly, many HIV experts 
would avoid abacavir, given the association of abacavir 
with CV endpoints in some but not all studies. From a 
bone and renal health standpoint, it is probably reason-
able to avoid TDF and use only TAF – however, some 
experts contend that the renal and BMD benefits to be 
expected from TAF [32] are not large enough to justify 
switching from TDF (now available as generic medica-
tion in many countries) to the more expensive TAF.
Finally, some HIV clinicians actively stop the “third 
agent” (TDF, ABC) for reasons of bone, renal, and CV 
health, arguing that evidence from randomized trial for 
the virological efficacy of dual therapy – using, e.g., 3TC 
and a protease inhibitor – is now solid [61, 62]. Those 
who avoid protease inhibitors are now using 3TC or 
FTC in combination with dolutegravir with success 
(dolutegravir monotherapy is not recommended today 
because the virological failure rate is too high), and vi-
rological failure with such dual therapy has been rare 
[63]. The manufacturer of dolutegravir is actively pur-
suing the dual therapy strategy by sponsoring large ran-
domized studies of 3TC in combination with dolutegra-
vir.
Conclusion
There is no doubt that we are seeing more elderly 
HIV-positive persons, and more of them have aging-re-
lated issues such as CV events, osteoporotic fractures, 
obesity, neurocognitive disorders, renal insufficiency, 
frailty, and DDIs than 20 years ago. However, the life ex-
pectancy of HIV-positive and HIV-negative persons is 
now essentially the same – this applies to most patients 
today who are not injecting drug users, non-smokers, 
and are treated with modern ART regimens. Adjustment 
for all relevant risk factors remains crucial in epidemio-
logical studies of aging-related complications in HIV. 
We await with interest further studies looking into the 
notion of accelerated aging in HIV – could this have been 
a premature conclusion and a problem perhaps not quite 
as bad as we feared?
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